Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Madison, Wisconsin 53792


The purpose of this study is to assess the impact of prospective drug level monitoring and dose-adjustment of nelfinavir (NFV) on the clinical and virologic outcomes in a group of HIV-infected patients who have achieved virologic success while receiving a nelfinavir containing highly active antiretroviral therapy (HAART) regimen.


Inclusion Criteria: - Antiretroviral naive or currently taking a nelfinavir containing HAART regimen where nelfinavir is the first protease inhibitor - Patients willing to comply with the protocol - Age greater than or equal to 18 years - Virologically successful if already on an established regimen Exclusion Criteria: - Prior use of a protease inhibitor exclusive of nelfinavir - Required use or concomitant use of drugs that may interact with or are contraindicated with nelfinavir - Use of immunomodulators or vaccines for HIV disease - Intercurrent illness at the time of enrollment that, in the clinician's judgement, could influence the HIV RNA concentration - Baseline ALT levels greater than five times the upper limit of normal



Primary Contact:

Principal Investigator
Andrew Urban, MD
University of Wisconsin, Madison

Backup Contact:


Location Contact:

Madison, Wisconsin 53792
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.